VCEL Vericel

Vericel to Participate in the BTIG Virtual MedTech Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021

Vericel to Participate in the BTIG Virtual MedTech Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021

CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18, 2021, at 3:00p.m. Eastern Time.

A live webcast of the event will be available on the Investor Relations section of the Vericel Corporation website at: .

About Vericel Corporation

Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at .

Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.

Investor Contacts:

Chad Rubin

Solebury Trout





EN
16/02/2021

Underlying

VCELVericel

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vericel

 PRESS RELEASE
Free
VCEL VERICEL

Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024

Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024 CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2024 financial results on Wednesday, May 8, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at . Please visit ...

April 24, 2024 1 EN
Free Trial
VCEL VERICEL

Vericel Corp: 1 director

A director at Vericel Corp sold/sold after exercising options 7,874 shares at 44.710USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...

03/14/24 March 14, 2024 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results an...

Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0 Million, with Adjusted EBITDA Growth of 50% Fourth Quarter Gross Margin of 75% and Adjusted EBITDA Margin of 34% Full-Year 2024 Total Revenue Guidance of $237 to $241 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanc...

February 29, 2024 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel to Present at the TD Cowen 44th Annual Health Care Conference ...

Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on Tuesday, March 5, 2024. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: ....

February 27, 2024 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results ...

Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024 CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of ...

February 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch